ArticleAmerican journal of respiratory and critical care medicine2010
Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
Article in American journal of respiratory and critical care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04016571 (Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Home versus hospital intravenous antibiotic therapy for cystic fibrosis.The Cochrane database of systematic reviews · 2015Pooled it
- Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Trial
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Trial
- Iron homeostasis during cystic fibrosis pulmonary exacerbation.Clinical and translational science · 2012Trial
- Pediatric outpatient parenteral antibiotic therapy: an important option for pediatric hospitals in Germany.GMS hygiene and infection control · 2026Article
- The effect of modulators on lung function following inpatient treatment for CF exacerbations.Frontiers in pediatrics · 2025Article
- Lung clearance index short-term variability in cystic fibrosis: a pre-post pulmonary exacerbation study.Italian journal of pediatrics · 2024Article
- Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Effect Modification between Genes and Environment and Parkinson's Disease Risk.Annals of neurology · 2022Review
- Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.Frontiers in pediatrics · 2022Review
- Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEVFrontiers in pediatrics · 2022Article
- Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.BMJ open respiratory research · 2021Article
- Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation.Journal of clinical medicine · 2021Article
- Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2021Review
- The effects of the addition of a new airway clearance device to chest physiotherapy in children with cystic fibrosis pulmonary exacerbations.Journal of mother and child · 2021Article
- Treatment of pulmonary exacerbations in cystic fibrosis.Current opinion in pulmonary medicine · 2020Review
- The future of cystic fibrosis care: a global perspective.The Lancet. Respiratory medicine · 2020Review
- Acute Pulmonary Exacerbations in Cystic Fibrosis.Seminars in respiratory and critical care medicine · 2019Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
rationaleIndividuals with cystic fibrosis (CF) are subject to recurrent respiratory infections (exacerbations) that often require intravenous antibiotic treatment and may result in permanent loss of lung function. The optimal means of delivering therapy remains unclear.
objectivesTo determine whether duration or venue of intravenous antibiotic administration affect lung function.
methodsData were retrospectively collected on 1,535 subjects recruited by the US CF Twin and Sibling Study from US CF care centers between 2000 and 2007. MEASUREMENTS AND MAIN
resultsLong-term decline in FEV₁ after exacerbation was observed regardless of whether antibiotics were administered in the hospital (mean, -3.3 percentage points [95% confidence interval, -3.9 to -2.6]; n = 602 courses of therapy) or at home (mean, -3.5 percentage points [95% confidence interval, -4.5 to -2.5]; n = 232 courses of therapy); this decline was not different by venue using t tests (P = 0.69) or regression (P = 0.91). No difference in intervals between courses of antibiotics was observed between hospital (median, 119 d [interquartile range, 166]; n = 602) and home (median, 98 d [interquartile range, 155]; n = 232) (P = 0.29). Patients with greater drops in FEV₁ with exacerbations had worse long-term decline even if lung function initially recovered with treatment (P < 0.001). Examination of FEV₁ measures obtained during treatment for exacerbations indicated that improvement in FEV₁ plateaus after 7-10 days of therapy.
conclusionsIntravenous antibiotic therapy for CF respiratory exacerbations administered in the hospital and in the home was found to be equivalent in terms of long-term FEV₁ change and interval between courses of antibiotics. Optimal duration of therapy (7-10 d) may be shorter than current practice. Large prospective studies are needed to answer these essential questions for CF respiratory management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.